The Manufacturers Life Insurance Company Makes New $591.08 Million Investment in Elevance Health, Inc. $ELV

Posted by Francis Steltz on Aug 25th, 2026

The Manufacturers Life Insurance Company acquired a new position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,528,416 shares of the company’s stock, valued at approximately $591,084,000.

A number of other large investors have also modified their holdings of the company. Jones Financial Companies Lllp acquired a new position in shares of Elevance Health in the second quarter valued at $5,133,000. Sone Capital Management LLC acquired a new stake in Elevance Health during the second quarter worth $5,140,000. Trajan Wealth LLC acquired a new stake in Elevance Health during the second quarter worth $41,315,000. Peak Asset Management LLC bought a new stake in Elevance Health in the 2nd quarter valued at $1,002,000. Finally, Fiduciary Financial Advisors bought a new stake in Elevance Health in the 2nd quarter valued at $45,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Up 0.5%

NYSE ELV opened at $402.62 on Tuesday. The firm has a market cap of $87.32 billion, a PE ratio of 17.89, a price-to-earnings-growth ratio of 2.29 and a beta of 0.68. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $436.24. The stock’s 50 day simple moving average is $394.79 and its 200 day simple moving average is $360.49. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The firm had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. During the same period last year, the firm posted $8.84 EPS. The business’s revenue was up .8% on a year-over-year basis. As a group, sell-side analysts forecast that Elevance Health, Inc. will post 27.18 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be paid a $1.72 dividend. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is 30.58%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ELV. Truist Financial raised their price objective on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. JPMorgan Chase & Co. upped their target price on shares of Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Deutsche Bank Aktiengesellschaft raised shares of Elevance Health from a “hold” rating to a “buy” rating and increased their price target for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. Mizuho raised their price target on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Finally, Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average target price of $440.90.

View Our Latest Analysis on Elevance Health

Insider Buying and Selling at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.34% of the company’s stock.

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.